The problem to be solved by the present invention is to provide an anticancer drug for treating tumors resistant to other antitumor drugs that inhibit FGFR, as well as a method for treating such tumors. The present invention provides an antitumor drug for administration to patients with tumors having resistance to FGFR inhibitors, containing a 3,5-disubstituted benzene alkynyl compound represented by the following general formula (I) or a salt thereof, as well as a therapeutic method employing the anticancer drug.
